In this research, CLS treatment might promote T cell differentiation and tumor immune response by inhibiting the expression of three TGF phenotypes (TGF-β1, TGF-β2, and TGF-β3), thereby inhibiting tumor angiogenesis and invasion. This evidence concerns the gene TGFB3 and neoplasm.